key: cord-0891492-0fxcq3aw
authors: Moritz, David; Krifors, Anders; Freyhult, Elisabeth; Månsson, Emeli
title: Seroprevalence and T‐cell response in 32 children 10 months after COVID‐19
date: 2022-02-15
journal: Acta Paediatr
DOI: 10.1111/apa.16287
sha: 8b4b5b8983753a3f567a55cbb95a82d44a99d59a
doc_id: 891492
cord_uid: 0fxcq3aw

nan

Protective cellular and humoral immune responses to SARS-CoV-2 have been found to persist 1 year after recovery from COVID-19 in adults. 1 Less is known about the kinetics of SARS-CoV-2 antibodies and T-cell memory response in children. We de- Thirty-two out of 52 eligible children were included in the study. The median age was 13.5 years (range 1.5-18 years). 19/32 (62%) participants were female. The most commonly reported symptoms were fever (23/32), fatigue (13/32), cough (12/32) and anosmia/ageusia (12/32). No child was hospitalised due to COVID-19. No re-infections were encountered during follow-up (10 months ± 7 days). The presence of anti-N IgG, anti-S IgG (including binding antibody unit [BAU] levels) and T-cell response towards SARS-CoV-2 antigens is presented by age-group in Table S1 . Anti-S IgG was detected in 25/32 (78%) of the children and anti-N IgG in 2/32 (6%). A T-cell response towards SARS-CoV-2 S1 was demonstrated in 17/32 (53%) and towards the combined SMNO-peptide pool in 20/32 (63%), with a concordance rate of 78%. All but two children with a T-cell response (to either the S1 peptide pool or the SMNO-peptide pool) were positive 

Additional supporting information may be found in the online version of the article at the publisher's website.

Overlapping immune responses in a cohort of 32 children with PCR-confirmed COVID-19. anti-N, directed against SARS-CoV-2 nucleocapsid protein; anti-S, directed against SARS-CoV-2 spike protein; IgG, immunoglobulin G; S1, spike protein domain 1; SNMO, spike nucleocapsid membrane open-reading frame

Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery

Mild SARS-CoV-2 infections and neutralizing antibody titers

Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum

SARS-CoV-2-specific B-and T-cell immunity in a population-based study of young Swedish adults

Children and adults with mild COVID-19 symptoms develop memory T cell immunity to SARS-CoV-2. medRxiv